Overall survival rates similar between intrahepatic cholangiocarcinoma and hepatocellular carcinoma

Key clinical point: Overall survival rates were similar in patients with intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) in a multivariate analysis. However, iCCA patients had better overall survival in a subgroup analysis of patients with poor prognostic features such as tumor size and lymph node involvement.

Major finding: Overall survival was 9 months for iCCA vs. 13 months for HCC, but this difference lost significance in multivariate analysis. In a subgroup analysis, overall survival was greater in iCCA compared to HCC for patients with tumors of 5 cm or larger (adjusted hazard ratio 0.83), lymph node involvement (aHR 0.76), distant metastasis (aHR 0.76), poorly/undifferentiated tumors (aHR 0.88) and patients receiving non-curative treatment (aHR 0.96).

Study details: The data come from the Surveillance, Epidemiology, and End Results Program 18 Database (2000-2017), and the study population included 13,611 iCCA patients and 96,151 HCC patients. 

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose

Source: Lee Y-T et al. Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.

Key clinical point: Overall survival rates were similar in patients with intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) in a multivariate analysis. However, iCCA patients had better overall survival in a subgroup analysis of patients with poor prognostic features such as tumor size and lymph node involvement.

Major finding: Overall survival was 9 months for iCCA vs. 13 months for HCC, but this difference lost significance in multivariate analysis. In a subgroup analysis, overall survival was greater in iCCA compared to HCC for patients with tumors of 5 cm or larger (adjusted hazard ratio 0.83), lymph node involvement (aHR 0.76), distant metastasis (aHR 0.76), poorly/undifferentiated tumors (aHR 0.88) and patients receiving non-curative treatment (aHR 0.96).

Study details: The data come from the Surveillance, Epidemiology, and End Results Program 18 Database (2000-2017), and the study population included 13,611 iCCA patients and 96,151 HCC patients. 

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose

Source: Lee Y-T et al. Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.

Key clinical point: Overall survival rates were similar in patients with intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) in a multivariate analysis. However, iCCA patients had better overall survival in a subgroup analysis of patients with poor prognostic features such as tumor size and lymph node involvement.

Major finding: Overall survival was 9 months for iCCA vs. 13 months for HCC, but this difference lost significance in multivariate analysis. In a subgroup analysis, overall survival was greater in iCCA compared to HCC for patients with tumors of 5 cm or larger (adjusted hazard ratio 0.83), lymph node involvement (aHR 0.76), distant metastasis (aHR 0.76), poorly/undifferentiated tumors (aHR 0.88) and patients receiving non-curative treatment (aHR 0.96).

Study details: The data come from the Surveillance, Epidemiology, and End Results Program 18 Database (2000-2017), and the study population included 13,611 iCCA patients and 96,151 HCC patients. 

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose

Source: Lee Y-T et al. Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.